Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.54 |
| ▸ | CNR1 | P21554 | 6/20 | 0.54 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10073859 | 0.97 | CNR2 (0.50) | CNR2CNR1PLA2G2AKDM4EALOX5 | |
| SCHEMBL10074638 | 0.95 | CNR2 (0.47) | CNR2CNR1KDM4EELANEKDM2B | |
| SCHEMBL2209862 | 0.83 | CNR1 (0.47) | CNR2CNR1PLA2G2AALOX5MTNR1B | |
| SCHEMBL13844050 | 0.82 | LMNA (0.46) | ELANE | |
| SCHEMBL13844057 | 0.81 | MEN1 (0.43) | CNR2CNR1ELANEHTR3A | |
| SCHEMBL13844051 | 0.81 | ELANE (0.45) | ELANE | |
| SCHEMBL13793977 | 0.81 | ELANE (0.47) | CNR2CNR1ELANE | |
| SCHEMBL10073875 | 0.80 | ELANE (0.44) | ELANE | |
| SCHEMBL13844052 | 0.80 | LMNA (0.48) | KDM4EELANE | |
| SCHEMBL10074207 | 0.80 | ELANE (0.44) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562909-B1 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK SHARP & DOHME (US) | 2012-06-27 | — | — | EP | disclosed |
| US-7547720-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547720-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2009-06-16 | — | — | US | disclosed |
| US-20070129418-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-06-07 | — | — | US | disclosed |
| US-20070129418-A1 | Ophthalmic compositions for treating ocular hypertension | MERCK SHARP & DOHME LLC | 2007-06-07 | — | — | US | disclosed |
| US-7196082-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196082-B2 | Ophthalmic compositions for treating ocular hypertension | MERCK & CO. INC. (US) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129418-A1 | Ophthalmic compositions for treating ocular hypertension | KCNH2, KCNJ11, KCNN1 | CNR2 744/4885CNR1 725/4885PLA2G2A 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.